Drugmakers face headwinds for patent filings; health care CEO earnings surge

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Federal patent initiatives could cause 'headwinds' for drugmakers and their broad filings By Ed Silverman Adobe "These are good initial steps that can help create a different culture," said Tahir Amin of I-MAK. who has advocated for reform at the USPTO. Read More STAT+: Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program By Ed Silverman Alex Hogan/STAT "Further delay of enforcement actions emboldens more manufacturers to begin overcharging safety net providers," the lawmakers wrote. Read More STAT+: Contract research organization to transfer 4,000 beagles from facility cited for inhumane care By Ed Silverman Jamie McCarthy/Getty Images "We hope the company and its management will be held criminally responsible," said Daphna Nachminovitch of the advocacy group PETA. Read More Sponsor content by STAT Events From trials to triumph: The 2022 STAT Summit Join us as we host silo-breaking discussions on the most important topics in health care. Over two days this November, you'll hear from some of the leading minds in the industry. Don't miss out, and enjoy early-bird pricing on your pass until July 22. Health care's high rollers: As the pandemic raged, CEOs' earnings surged By Bob Herman and Kate Sheridan and J. Emory Parker and Adam Feuerstein and Mohana Ravindranath Mike Reddy for STAT Health care's top executives are cushioned more than ever by the rising fortunes of their stock ownership. Read More STAT+: Biotech executives pull in some of health care's biggest paydays, with Regeneron's CEO sitting atop the pack By Adam Feuerstein Illustration: STAT; Photo: AP Regeneron's chief executive, Len Schleifer, took home $453 million in 2021, more than any other biotech CEO, according to a STAT analysis. Read More Monday, July 18, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser